Respiratory Video Recap—March 6, 2026

Respiratory biweekly video recap covering regulatory milestones, clinical trial progress, early data updates, strategic deals, and innovation programs across the respiratory landscape. This edition highlights developments spanning rare lung disease, pulmonary hypertension, fibrosis, vaccines, and AI-enabled care initiatives.

🎯 Watch Our Video Summary Capturing Respiratory News from the Last Two Weeks

🗓️ Explore weekly details and sources

• Week 20–26 February 2026
• Week 27 February–5 March 2026

📚 See the full Respiratory archive on our research hub page.

Top Stories Covered in This Video

Chapters

0:00 Introduction
0:08 Savara’s MOLBREEVI BLA accepted for autoimmune pulmonary alveolar proteinosis
0:46 Tessera’s TSRA-196 gene-editing therapy gains Fast Track and Orphan Drug designations
1:19 AstraZeneca launches A.Catalyst Network Thailand Hub for AI-enabled lung screening
1:49 Aclaris initiates Phase 1b asthma trial for bispecific antibody ATI-052
2:21 GSK agrees to acquire 35Pharma to expand pulmonary hypertension pipeline with HS235
2:50 SK bioscience, IDT Biologika, and Vaxxas advance influenza patch vaccines with EU funding
3:19 Rein Therapeutics doses first patient in Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis
3:44 BioVersys publishes Phase 1 data for BV100 while advancing global registrational program
4:10 How to reach us

Transcript

Welcome to the latest edition of Respiratory Research Updates, covering key developments from the past two weeks. Brought to you by LucidQuest.

Savara has announced that the U.S. Food and Drug Administration has filed the biologics license application for MOLBREEVI, an inhaled molgramostim therapy for autoimmune pulmonary alveolar proteinosis. The application has received Priority Review, with a PDUFA target action date set for August 22, 2026. If approved, MOLBREEVI could become the first FDA-approved therapy for this rare lung disorder, potentially changing the treatment landscape for patients with autoimmune PAP.

Tessera Therapeutics has received both Fast Track and Orphan Drug designations from the FDA for TSRA-196, an in vivo gene-editing therapy designed to treat adults with alpha-1 antitrypsin deficiency who carry the PiZZ mutation. The program is currently being evaluated in a first-in-human Phase 1/2 study and represents a potential one-time therapeutic approach aimed at correcting the underlying genetic cause of the disease.

AstraZeneca Thailand has launched the A.Catalyst Network Thailand Hub, a collaborative initiative involving public, private, academic, and patient stakeholders to accelerate AI-enabled healthcare innovation. One of the first initiatives under this program is an AI-assisted lung screening effort targeting industrial workers across four Thai provinces using mobile chest X-ray technology and digital health education.

Aclaris Therapeutics has initiated a Phase 1b randomized, double-blind, placebo-controlled proof-of-concept trial of ATI-052 in patients with asthma who are currently receiving GINA step two to four therapies. ATI-052 is a bispecific antibody targeting TSLP and IL-4 receptor alpha, and topline results from the study are expected in the second half of 2026.

GSK has entered into an agreement to acquire Canada-based biotechnology company 35Pharma for approximately $950 million in cash. The acquisition adds HS235, a clinical-stage activin receptor signaling inhibitor, to GSK’s pipeline, with planned development in pulmonary arterial hypertension and pulmonary hypertension associated with heart failure with preserved ejection fraction.

SK bioscience, IDT Biologika, and Vaxxas have been selected for an EU-supported program to develop high-density microarray patch influenza vaccines. The initiative will fund Phase 1 clinical development for seasonal and pandemic influenza vaccines using the HD-MAP platform, with the goal of improving vaccine accessibility and simplifying administration.

Rein Therapeutics has dosed the first patient in a Phase 2 randomized, placebo-controlled clinical trial evaluating inhaled LTI-03 for idiopathic pulmonary fibrosis. The study plans to enroll approximately 120 patients across multiple countries, and interim data are expected in the second half of 2026.

Finally, BioVersys has published Phase 1 clinical data for BV100, reporting dose-proportional pharmacokinetics and favorable tolerability in healthy volunteers. The company is continuing development of BV100, which is currently being studied in a global Phase 3 program for infections caused by carbapenem-resistant Acinetobacter baumannii.
Stay ahead in Respiratory Research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why It Matters

• Savara’s BLA filing puts MOLBREEVI closer to a potential first approved therapy for autoimmune PAP in the US [1].
• Tessera’s designations add regulatory support for an in vivo gene-editing approach in AATD, an area with limited causal treatment options [2].
• Aclaris is advancing ATI-052 across asthma and atopic dermatitis, aiming to validate a dual-pathway biologic strategy [4].
• GSK’s 35Pharma deal reinforces strategic interest in pulmonary hypertension assets with differentiated profiles [5].
• The SK bioscience, IDT, and Vaxxas consortium highlights continued public funding for alternative vaccine delivery platforms in Europe [6].

🗓️ Explore weekly details and sources

• Week 20–26 February 2026
• Week 27 February–5 March 2026

📚 See the full Respiratory archive on our research hub page.